Scaling Synthetic Biology (with Ginkgo’s Reshma Shetty)

Science is getting better at re-engineering micro-organisms for all kinds of uses, from better medical treatments to more durable materials. But there are still hurdles to overcome, including scaling the process.

Boston-based Ginkgo Bioworks was one of the first billion-dollar companies in the synthetic biology space. The NYSE-listed company uses machine learning and automation to coax biology to work at industrial scale. COO Reshma Shetty talks to Azeem Azhar about the company’s technology, business model, and how big she thinks synthetic biology could become.

@Azeem (twitter.com/azeem)

@exponentialview (twitter.com/exponentialview)

@reshmapshetty (twitter.com/reshmapshetty)

Further resources:

The Bio Revolution: Innovations transforming economies, societies, and our lives (mckinsey.com/industries/life-sciences/our-insi…) – McKinsey, May 2020

Engineering Biology: The Next Frontier (hbr.org/podcast/2020/06/engineering-biology-th…) – Exponential View Podcast ft. Vijay Pande, June 2020

The Next Trillion-Dollar Market (hbr.org/podcast/2020/04/the-next-trillion-doll…) – Exponential View Podcast ft. Deep Nishar, April 2020

About Exponential View:
Welcome to Exponential View, where Azeem Azhar examines how exponential technologies such as AI are reshaping the future. Each week, Azeem shares his analysis or speaks with an expert guest to shed light on frontier shifts across technology, business and society.

To keep up with the Exponential transition, subscribe to this channel or the newsletter: exponentialview.co/
To keep up with our AI economy research, subscribe to investmentbrief.ai

Where to find me:
Exponential View newsletter: exponentialview.co
Website: azeemazhar.com
LinkedIn: linkedin.com/in/azeem
Twitter/X: x.com/azeem

Production by EPIIPLUS1.
Production and research: Baba Films, Marija Gavrilov.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.